Condition
SGLT 2 Inhibitors clinical trials and research
As of November 12, 2026, Find a Trial lists 2 SGLT 2 Inhibitors clinical trials that are recruiting, at sites in 2 countries (most in Lebanon (1), China (1)). By phase: Phase 4 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Canagliflozin added to immunotherapy for advanced solid tumors
This study tests whether adding canagliflozin to tislelizumab-based immunotherapy helps people with unresectable or metastatic solid tumors.
-
Empagliflozin to reduce inflammation after coronary stenting
This trial will test whether taking empagliflozin for three days before elective PCI reduces the rise in C‑reactive protein and other inflammatory markers in people with stable coronary artery disease.
Related topics
Quick answers
How many SGLT 2 Inhibitors clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Lebanon (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.